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practice environments including inpatient/out-patient
pharmacy, clinics, managed care, and LTC. The wide-
spread applicability of the DSMT will be beneficial to
healthcare practitioners, administrators, and researchers
with diverse interests from managed care organizations,
long term care, hospitals, community settings, and educa-
tional institutions.
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Traditional state Medicaid programs that adopt an open
managed care model must adapt their oversight from a
single drug formulary to multiple formularies. Following
the workshop, participants should be able to identify and
describe successful strategies for obtaining and analyzing
data needed to evaluate appropriateness of multiple drug
formularies. Practical experience with obtaining informa-
tion and creating a database containing multiple formu-
laries, procedures to incorporate analysis of drug therapy
by disease state, and different methods used to categorize
drugs for evaluation will be presented. These will be dem-
onstrated by comparing medications used for the treat-
ment of peptic ulcer disease by Medicaid managed care
formularies in the state of Tennessee. This workshop is
intended for government and healthcare industry decision
makers and others involved in quality control and im-
provement.
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The constraints on healthcare delivery have created de-
mand for intervention analyses that address the "real
world," naturalistic setting. Retrospective databases can
provide a naturalistic view of drug and service utilization
derived from administrative data. However, there are
times when administrative data does not fully address de-
cision-makers' questions. When this is the case, prospec-
tive non-randomized studies represent another approach
that can collect more comprehensive data. This workshop
will explore the development and implementation of such
a study, the Schizophrenia Care and Assessment Program
(SCAP). SCAP evaluates the relationship between usual
medical care as delivered in various health systems and
clinical, humanistic, and economic outcomes for patients
with schizophrenia. SCAP is currently enrolling in the
United States and Australia where each patient will be
89
followed for three years. The total sample will be 2,700
participants. The workshop will cover three development
stages of this project: (1) retrospective view of drug and
service utilizations patterns, (2) protocol development,
(3) site start-up and baseline characteristics of the enroll-
ees. The use pattern portion of the workshop will discuss
methods appropriate for analyses in retrospective data-
base studies. The protocol development section will dis-
cuss instrument development, instrument selection, and
administration for the setting of a naturalistic study. The
site start-up and baseline characteristics section will dis-
cuss training and enrollment issues in a study of this size
and the practical issues surrounding MIS resource use
data. Early baseline characteristics on an expected sample
of 250 U.S. enrollees will also be discussed. Attendees
will gain an understanding of design and implementation
issues in naturalistic settings for marketed products. Pro-
fessionals who expect to be involved in prospective out-
comes studies or who are interested in exploring this op-
tion should attend.
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In 1997, the United States Pharmacopeia (USP) estab-
lished an Ad Hoc Outcomes/Cost Effectiveness Advisory
Panel to consider the development of specifications for
compiling, indexing, and evaluating outcomes research!
cost-effectiveness literature on a disease-specific basis.
Such a resource could be used to support pharmaceutical
therapy choice decision making by a variety of potential
users. The USP has developed a protype health outcomes
and pharmacoeconomic annotated registry of the litera-
ture on the disease state, congestive heart failure. Other
organizations have established and are marketing phar-
macoeconomic and health outcome literature registries,
with two examples being the HEED database (OHE-IF-
PMA Database Ltd.) and the University of York NHS
Centre for Reviews and Dissemination (DARE).
OBJECTIVE: To share experiences and to identify the
needs of decision makers for outcome/pharrnacoeco-
nomic information and to discuss whether they are being
met by currently available literature sources. Decision
makers include health care practitioners, managed care
organizations, third party payers, industry and govern-
ments.
WORKSHOP FORMAT: The USP congestive heart fail-
ure protype literature registry will be described and com-
pared to currently available pharmacoeconomic/outcome
databases. Participants will share their assessment of the
currently available abstracting service/databases and de-
termine if there is a role for further developments.
DESIRED OUTCOME: To determine if there is a need
for a collaborative approach among interested parties to
make relevant health outcome/pharmacoeconomic infor-
